Severe hepatic toxicity after administration of infliximab in psoriasis treatment

##plugins.themes.bootstrap3.article.main##

##plugins.themes.bootstrap3.article.sidebar##

Published Dec 31, 2014
DOI: https://doi.org/10.22551/2014.04.0103.10023
Oana Gabriela Chiriac
"Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania,
Anca Trifan
"Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania, Gastroenterology and Hepatology Clinic, “Sf. Spiridon” Clinical Emergency Hospital, Iasi, Romania
Ana Maria Singeap
"Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania, Gastroenterology and Hepatology Clinic, “Sf. Spiridon” Clinical Emergency Hospital, Iasi, Romania
Camelia Cojocariu
"Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania, Gastroenterology and Hepatology Clinic, “Sf. Spiridon” Clinical Emergency Hospital, Iasi, Romania
Carol Stanciu
"Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania, Gastroenterology and Hepatology Clinic, “Sf. Spiridon” Clinical Emergency Hospital, Iasi, Romania
Catalin Sfarti
"Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania, Gastroenterology and Hepatology Clinic, “Sf. Spiridon” Clinical Emergency Hospital, Iasi, Romania

Abstract

The true incidence of drug-induced liver injury (DILI) is difficult to discern because of an unknown denominator of individuals receiving a drug, lack of a simple objective test for the diagnosis of DILI, lack of consensus on what liver test abnormalities constitute DILI, difficulty in attribution of causation to a single drug in those on many medicines, and lack of systematic reporting. Over 1000 medications and herbal products have been involved in causing liver injury, and the list continues to grow. Regarding the biologic therapy with infliximab, according to specialized studies, usually there were mild to moderate elevations of liver enzymes. Hereby, we present a clinical case of drug-induced hepatitis, after the administration of monoclonal antibodies over six months, with a remarkable contrast between the major biochemical changes and the absence of any symptoms.

##plugins.themes.bootstrap3.article.details##

Keywords

biologic therapy, infliximab, psoriasis, liver injury, DILI

References
1. Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Saf 2007; 30:277–294.
2. Leise MD, Poterucha JJ, Talwalkar JA. Drug induced liver injury. Mayo Clinic proceedings. 2014; 89(1):95-106.
3. Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug induced liver injury. World J Gastroenterol 2008; 14(44):6774-85.
4. Ghabril M, Bonkovsky HL, Kum C, et al. Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol 2013; 11(5):558–564.
5. Grant LM, Rockey DC. Drug induced liver injury. Curr Opin Gastroenterol 2012; 28(3):198-202.
6. Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010; 51(2):615-20.
7. Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug induced liver injury in the United States. Gastroenterology 2008; 135(6):1924-34.
8. Uetrecht J. Idiosyncratic drug reactions: past, present and future. Chem Res Toxicol 2008; 21(1):84-92.
9. Liss G, Rattan S, Lewis JH. Predicting and preventing acute liver injury. Whats new in 2010? Expert Opin Drug Metab Toxicol 2010; 6(9):1047- 61.
10. Bernal, Auzinger G, Dhawan A, Wendon J. Acute liver failure. Lancet 2010; 376(9736):190-201.
How to Cite
Chiriac, O. G., Trifan, A., Singeap, A. M., Cojocariu, C., Stanciu, C., & Sfarti, C. (2014). Severe hepatic toxicity after administration of infliximab in psoriasis treatment. Archive of Clinical Cases, 1(3), Arch Clin Cases 2014; 1(3):108-111. https://doi.org/10.22551/2014.04.0103.10023
Issue
Vol. 1 No. 3 (2014)
Section
Case Reports

Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.

Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.

Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.

How to Cite

Chiriac, O. G., Trifan, A., Singeap, A. M., Cojocariu, C., Stanciu, C., & Sfarti, C. (2014). Severe hepatic toxicity after administration of infliximab in psoriasis treatment. Archive of Clinical Cases, 1(3), Arch Clin Cases 2014; 1(3):108-111. https://doi.org/10.22551/2014.04.0103.10023